Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $431 | $397 | $0 | $0 |
| Gross Profit | -$431 | -$397 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $4,735 | $2 | $1 |
| SG&A Expenses | $3,108 | $4,735 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,773 | $0 | $1 |
| Operating Expenses | $3,108 | $2,963 | $3 | $2 |
| Operating Income | -$3,539 | -$3,360 | -$3 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,334 | -$155 | -$0 | -$0 |
| Pre-Tax Income | -$6,873 | -$3,515 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,870 | -$5,616 | -$3 | -$2 |
| % Margin | – | – | – | – |
| EPS | -1.94 | -1 | -0.92 | -0.78 |
| % Growth | -94% | -8.7% | -17.9% | – |
| EPS Diluted | -1.94 | -1 | -0.92 | -0.78 |
| Weighted Avg Shares Out | 3,536 | 3,505 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3,536 | 3,505 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $0 | $0 |
| Interest Expense | $165 | $162 | $0 | $0 |
| Depreciation & Amortization | $431 | $230 | $0 | $0 |
| EBITDA | -$6,277 | -$2,455 | -$2,691 | -$1 |
| % Margin | – | – | – | – |